You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Personalizing Acute Myeloid Leukemia Therapy in Patients Without Targetable Mutations 

  • Authors: Harry P. Erba, MD, PhD; Laura J. Zitella, MS, RN, ACNP-BC, AOCN
  • CME / ABIM MOC / CE Released: 1/27/2022
  • Valid for credit through: 1/27/2023
Start Activity

Target Audience and Goal Statement

This activity is intended for community-based hematologists/oncologists, nurses, nurse practitioners, and pharmacists.

The goal of this activity is to improve the knowledge of the community-based acute myeloid leukemia (AML) care team about options for patients with AML without actionable targets so they can select therapy and manage side effects.

Upon completion of this activity, participants will:

  • Have greater competence related to
    • Personalizing treatment for patients with AML without actionable targets
    • Managing the side effects of AML treatment regimens
  • Have greater confidence in their ability to
    • Work in an interprofessional team to address treatment-related side effects of AML therapies


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.


  • Harry P. Erba, MD, PhD

    Professor of Medicine
    Leukemia Program
    Duke University
    Durham, North Carolina


    Disclosure: Harry P. Erba, MD, PhD, has the following relevant financial relationships:
    Advisor or consultant for: AbbVie, Inc.; Agios Pharmaceuticals; Astellas; Bristol Myers Squibb Company; Celgene Corporation; Daiichi Sankyo, Inc.; Genentech; GlycoMimetics; Immunogen; Incyte Corporation; Jazz Pharmaceuticals, Inc.; Kura Oncology; Macrogenics; Novartis; Pfizer, Inc.; Syros; Trillium
    Speaker or a member of a speakers bureau for: AbbVie, Inc.; Agios Pharmaceuticals/Servier; Bristol Myers Squibb Company; Celgene Corporation; Incyte Corporation; Jazz Pharmaceuticals, Inc.; Novartis
    Grants for clinical research from: AbbVie, Agios/Servier, ALX Oncology, Ascentage; Daiichi Sankyo; Forty-Seven/Gilead; Jazz Pharmaceuticals; Kura Oncology; Novartis; PTC
    Other: Chair; Independent Review Committee; VIALE A and VIALE C; AbbVie Chair; Steering Committee; AML/MDS Registry Study; Bristol Myers Squibb/Celgene Member; Scientific Steering Committee, Phase III study of uproleselan, Glycomimetics

  • Laura J. Zitella, MS, RN, ACNP-BC, AOCN

    Hematology/Oncology Nurse Practitioner
    Associate Clinical Professor
    University of California San Francisco
    San Francisco, California


    Disclosure: Laura J. Zitella, MS, RN, ACNP-BC, AOCN, has no relevant financial relationships.


  • Heather P. Friedman, MPH

    Medical Education Director, Medscape, LLC


    Disclosure: Heather P. Friedman, MPH, has disclosed no relevant financial relationships.

  • Yoji Yamaguchi, MA, ELS

    Scientific Content Manager, Medscape, LLC


    Disclosure: Yoji Yamaguchi, MA, ELS, has disclosed no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Disclosure: Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape, LLC designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number JA0007105-0000-22-010-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Personalizing Acute Myeloid Leukemia Therapy in Patients Without Targetable Mutations 

Authors: Harry P. Erba, MD, PhD; Laura J. Zitella, MS, RN, ACNP-BC, AOCNFaculty and Disclosures

CME / ABIM MOC / CE Released: 1/27/2022

Valid for credit through: 1/27/2023


Assessment Survey

Before you begin, please take this brief survey.

  • Print